The Economic Freedom Fighters (EFF) has called for the immediate resignation of Health Minister Dr Aaron Motsoaledi following serious procurement failures in the R15.5 billion national antiretroviral (ARV) tender and a Pretoria High Court ruling against the Department of Health.
The legal challenge was brought by pharmaceutical manufacturer Cipla after contracts were awarded under the high-value ARV tender. The EFF argues that the court’s findings vindicate warnings the party raised earlier in the year and demonstrate that political leadership at the health department can no longer evade accountability for billions of rands in public procurement.
Early Warnings in Parliament
According to the EFF, the party repeatedly flagged red flags while the procurement dispute was still unfolding and pushed for parliamentary oversight before the situation worsened.
- 14 February 2026: The EFF formally wrote to the Chairperson of the Portfolio Committee on Health requesting an urgent meeting to address concerns surrounding the R15.5 billion ARV tender.
- 18 February 2026: During Portfolio Committee proceedings, EFF Member of Parliament Naledi Chirwa directly confronted Motsoaledi over the award of contracts and the department’s handling of the tender.
During that engagement, Chirwa and the EFF raised five core issues:
- Common ownership: Contracts were awarded to Barrs Pharmaceuticals and Innovata Pharmaceuticals, companies linked under the Avacare Health Group.
- Bid pricing anomalies: The two entities submitted suspiciously similar prices, including a difference of just R1 on a specific product, raising concerns about potential collusion.
- Financial due diligence: The department failed to conduct adequate financial evaluations to determine whether the bidders could fulfil multibillion-rand supply commitments.
- PFMA accountability: Questions arose over compliance with the Public Finance Management Act (PFMA) and holding officials responsible for procurement decisions.
- Investigations and re-tendering: The party called for a Special Investigating Unit (SIU) probe and for the tender process to be restarted.
A public statement issued by the Portfolio Committee on 19 February 2026 subsequently reflected many of these concerns, pointing to questions around financial due diligence, common shareholdings, local manufacturing, and procurement choices.
“Convenient Distancing” and Business Rescue Fallout
The EFF criticised Motsoaledi’s response in Parliament, accusing him of attempting to distance himself from the tender process by stating that he does not involve himself in tenders and relies on information supplied by departmental officials.
“A Minister cannot preside over a Department responsible for the health of millions of people and then claim ignorance when billions in public procurement are surrounded by serious irregularities.” — said the EFF.
The party also pointed to developments after the awards: Barrs and Innovata entered business rescue in December 2025, with Hetero featuring in subsequent supply arrangements. For the EFF, those events underscored the need for a thorough probe into how contracts were allocated and managed.
High Court Findings and Costs
The Pretoria High Court ruling in the matter brought by Cipla dealt a sharp blow to the health department. According to the EFF, the court found that Innovata and Viatris did not hold valid manufacturing licences for their Isando manufacturing site when the tender closed.
The court also identified serious irregularities in how local manufacturing preferences and historically disadvantaged individual (HDI) points were allocated, and directed the department to investigate whether Barrs and Innovata prepared their bids independently. In addition, both the Minister and the Director-General were ordered to pay Cipla’s legal costs.
Seven-Point Demand
In the wake of the judgment, the EFF has laid out a sweeping set of demands covering leadership accountability, enforcement, supply security, and industrial policy:
- Resignation: The immediate resignation of Health Minister Dr Aaron Motsoaledi.
- SIU investigation: A comprehensive investigation by the Special Investigating Unit into the R15.5 billion ARV tender and all implicated officials and companies.
- Competition probe: An investigation by the Competition Commission into possible collusion between Barrs and Innovata.
- Full disclosure: Complete release of tender evaluation, adjudication, and financial due-diligence reports.
- Official accountability: Action against officials responsible for unlawful procurement decisions under the PFMA.
- Supply continuity: A comprehensive plan to safeguard uninterrupted ARV supplies while affected tender awards are reconsidered.
- State manufacturing: Accelerated establishment of state pharmaceutical manufacturing capacity to reduce reliance on private pharmaceutical firms.
Whether the pressure from the opposition translates into political consequences or new enforcement action now rests with the executive, oversight bodies, and investigative agencies as the fallout from the R15.5 billion tender continues to play out.


